alectinib
The subcutaneous Perjeta-Herceptin formulation, Phesgo, was a top driver of sales growth in the first quarter of 2025.
UK's NICE Recommends Alecensa as Adjuvant Treatment for ALK-Positive Lung Cancer
The agency based its decision on results from the Phase III ALINA trial in which Alecensa improved disease-free survival in ALK-positive NSCLC patients.
Roche Reports 5 Percent CER Growth in Pharmaceutical Sales Driven by Strong Phesgo Uptake
In the first half of the year, sales of the injectable formulation of HER2-targeted agent grew 60 percent at CER, compared to H1 2023.
European Commission Approves Alecensa as Adjuvant Treatment for ALK-Positive Lung Cancer
Treatment with Alecensa after surgery reduced the risk of recurrence or death by 76 percent compared to chemo in patients with early-stage ALK-positive lung cancer.
Pfizer's Lorbrena Produces Longest Progression-Free Survival Seen in ALK-Positive NSCLC Patients
At five years, 60 percent of patients receiving first-line Lorbrena were alive without progression, according to Phase III data reported at ASCO.
Feb 3, 2023
Jul 22, 2021
Roche Q2 Pharmaceutical Revenues Increase 4 Percent
Oct 1, 2019